Dehydrocorydaline nitrate

TargetMol
Product Code: TAR-T2S2362
Supplier: TargetMol
CodeSizePrice
TAR-T2S2362-1mg1mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2S2362-1mL1 mL * 10 mM (in DMSO)£292.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2S2362-5mg5mg£292.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2S2362-10mg10mg£445.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2S2362-25mg25mg£680.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2S2362-50mg50mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
1. Dehydrocorydaline(DHC) not only inhibits antibody-mediated allergic reactions but also influences cell-mediated allergic reactions, and the inhibitory effect of Corydalis Tuber on allergic reactions may be partially attributed to DHC. 2. Dehydrocorydaline can inhibit elevated mitochondrial membrane potential in lipopolysaccharide-stimulated macrophages. 3. Dehydrocorydaline has antinociceptive effects in mouse models of inflammatory pain, the effects involve the opioid receptor and inflammatory cytokines. 4. Dehydrocorydaline has anti-inflammatory activity.
CAS:
13005-09-9
Formula:
C22H24N2O7
Molecular Weight:
428.441
Pathway:
Microbiology/Virology; MAPK; DNA Damage/DNA Repair; Autophagy; Apoptosis; ; Chromatin/Epigenetic; Proteases/Proteasome
Purity:
0.9979
SMILES:
[O-][N+]([O-])=O.COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC
Target:
BCL; PARP; p38 MAPK; Caspase; Parasite; Autophagy

References

1. Ishiguro K , Ando T , Maeda O , et al. Dehydrocorydaline inhibits elevated mitochondrial membrane potential in lipopolysaccharide-stimulated macrophages[J]. International Immunopharmacology, 2011, 11(9):0-1367.